Wegovy and Liver Disease (MASH): What the UK Licence Covers

In the UK SmPC, Wegovy is licensed for weight management and cardiovascular risk reduction, not as a treatment for MASH (metabolic dysfunction-associated steatohepatitis) or fatty liver disease. So this guide does not claim it as a UK liver-disease treatment. Weight management is generally relevant to fatty liver because the two are linked, but that is different from a licensed MASH indication. The ESSENCE trial is beyond the UK licence and this corpus, so a clinician should advise on any liver-specific use.

There is growing interest in whether weight-loss medicines like Wegovy can help fatty liver disease, now often called MASH, and you may have seen mention of a trial called ESSENCE. The honest, UK-based answer is more limited than the headlines: Wegovy is not licensed for MASH in the UK, even though weight is closely linked to fatty liver.

This guide explains whether Wegovy is licensed for liver disease (MASH) in the UK, what the SmPC actually covers, why weight management is relevant to fatty liver, and what to discuss. It draws on the UK Summary of Product Characteristics and the NHS. Liver disease should be managed with your liver or specialist team.

Is Wegovy a treatment for MASH or fatty liver?

It is worth being precise about the UK position. In the UK SmPC, Wegovy's licensed indications are weight management and cardiovascular risk reduction, not a treatment for MASH (metabolic dysfunction-associated steatohepatitis), the more advanced form of fatty liver disease, or for fatty liver generally ¹. So this guide does not present it as a UK liver-disease treatment ¹.

MASH and fatty liver are strongly linked to excess weight, which is the basis for the interest in weight-loss medicines, but a general link is different from a specific licensed indication¹. The distinction matters for setting accurate expectations ¹.

So if your interest in Wegovy is driven by a fatty liver or MASH diagnosis, the honest position is that it is a weight-management and cardiovascular medicine in the UK, whose relevance to your liver is for a specialist to judge, not a licensed liver treatment ¹².

This is a fast-moving area, and it is one where headlines can get ahead of the UK licensing position ¹. There has been genuine research interest in semaglutide for MASH, and other regulators or future updates may change the picture, but a guide bound to the current UK SmPC can only describe what is licensed now ¹. Being clear about that, rather than implying a liver indication that does not yet exist in the UK, is the responsible approach for a topic this consequential ¹.

What MASH is

MASH (metabolic dysfunction-associated steatohepatitis), part of the spectrum once called non-alcoholic fatty liver disease, involves a build-up of fat in the liver together with inflammation and, over time, the risk of scarring ². It is closely associated with obesity, type 2 diabetes and related metabolic conditions ².

Because of that association, weight management is part of the general approach to fatty liver in people who are overweight, which is why weight-loss medicines come up in this context ². But MASH itself is diagnosed and managed by liver specialists, often as part of wider metabolic care ².

This guide gives only a brief, general description of MASH; your liver team is the right source for what it means for you and how it is managed ². The point here is the licensing position of Wegovy, not the management of MASH itself ¹².

Why weight management is relevant to fatty liver

The connection is the weight. Because fatty liver and MASH are strongly linked to excess weight and metabolic factors, losing weight is a recognised part of managing fatty liver in people who are overweight ². So weight management, which Wegovy is licensed for, addresses a factor relevant to the liver condition ¹².

That is the honest, indirect connection: Wegovy is licensed for the weight, and the weight is connected to fatty liver, rather than the medicine being a direct, licensed liver treatment in the UK ¹. Framing it that way avoids overstating what the licence supports ¹.

It also means any role for the medicine in your liver condition specifically is a question for your liver team, in the context of your overall metabolic care, not something the UK licence settles ¹².

Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.

The ESSENCE trial and what is beyond this guide

You may have read about ESSENCE, a trial investigating semaglutide in MASH. It is important to be clear that the ESSENCE trial and its findings are beyond the UK licence and beyond the sources this guide is based on, so this guide does not describe its results or use them to make claims about Wegovy for MASH ¹.

Investigational trial findings are not the same as a licensed indication: a trial may explore a possible use, but until and unless that translates into a licensed indication in the SmPC, this guide treats it as outside what can be claimed ¹. The UK SmPC, as it stands here, does not include a MASH indication ¹.

So if you have seen ESSENCE discussed, a clinician is the right person to put it in context and to advise on whether any liver-specific use is appropriate for you, rather than relying on a general guide ¹². This guide stays within the UK licensing position ¹.

The reason for this caution is not to be unhelpful but to avoid the real harm of overstating a treatment for a serious condition ¹. Someone with MASH could be misled into thinking a weight-loss medicine is a licensed cure, or into neglecting their specialist liver care, if a guide implied more than the UK licence supports ¹². Pointing you to your liver team for anything liver-specific, while being honest about what is and is not licensed, is the safer service ¹².

What this means now

In practical terms, in the UK now, Wegovy is licensed for weight management and cardiovascular risk reduction, and any relevance to fatty liver is through the weight connection rather than a licensed liver indication ¹. So eligibility runs through the weight-management route ¹.

If you have fatty liver or MASH and obesity, weight management may be relevant to your liver because of that link, but it does not replace the assessment and management your liver team provides ¹². Both should be considered together ¹².

It also means not assuming a weight-loss medicine will treat your liver condition directly; that is a matter for specialist assessment, not an assumption ². Our guide on Mounjaro and liver disease takes the same honest stance for the related medicine ¹.

If you are eligible for weight management and also have fatty liver, the sensible way to think about it is that any benefit to the liver would come indirectly, through the weight loss, and would be monitored by your liver team rather than assumed ¹². That keeps expectations realistic: weight management is a legitimate goal in its own right, and its relevance to the liver is something a specialist tracks rather than a licensed promise ¹². Keeping that distinction clear protects you from expecting a liver cure the licence does not offer ¹.

What to discuss with your prescriber or liver team

If fatty liver or MASH is part of your picture, tell your prescriber and your liver team, so weight management and liver care are coordinated ¹². Cover your eligibility for weight-management treatment and how any weight loss should be reflected in your liver monitoring ¹.

Be clear that, in the UK, the medicine is used for weight management (and, where relevant, cardiovascular risk), with fatty liver as a related condition, rather than as a licensed liver treatment ¹. If you have read about ESSENCE, ask your liver team to put it in context for you ¹². The aim is to be accurate about the current UK position rather than to imply more than the licence supports for a serious condition ¹.

Our guide on how Wegovy works covers the medicine more broadly. For liver disease, the headline is that the UK licence covers weight management and cardiovascular risk, not MASH, and any liver-specific role is for a specialist to judge, with the ESSENCE trial sitting beyond the current UK position ¹².

If the picture changes, for instance if a liver indication is licensed in the UK in future, that is something a clinician and updated guidance would reflect ¹. For now, the responsible position is to use Wegovy for what it is licensed for, keep your liver care with your specialist, and treat any trial-based or overseas claims as context for a clinical conversation rather than as the current UK position ¹².

Frequently asked questions

Is Wegovy licensed for fatty liver disease or MASH in the UK?

No. In the UK SmPC, Wegovy is licensed for weight management and cardiovascular risk reduction, not as a treatment for MASH or fatty liver disease, so this guide does not claim it as a UK liver-disease treatment ¹. Weight is linked to fatty liver, but that is a general connection, not a licensed indication ¹.

What is MASH?

MASH (metabolic dysfunction-associated steatohepatitis), part of the fatty liver spectrum, involves fat build-up in the liver with inflammation and, over time, a risk of scarring, and is closely linked to obesity and type 2 diabetes ². It is diagnosed and managed by liver specialists ².

Can losing weight on Wegovy help fatty liver?

Fatty liver is strongly linked to excess weight, and weight loss is a recognised part of managing it in people who are overweight, which is the basis for the interest here ². But this is the weight connection, not the medicine being a licensed liver treatment in the UK; your liver team manages the condition ¹².

What about the ESSENCE trial for Wegovy and MASH?

The ESSENCE trial is beyond the UK licence and the sources this guide is based on, so this guide does not describe its results or use them to make claims about Wegovy for MASH ¹. Trial findings are not the same as a licensed indication; a clinician can put ESSENCE in context for you ¹².

Can I get Wegovy on the NHS for liver disease?

In the UK, access runs through the weight-management (or cardiovascular) route, not a liver indication, since Wegovy is not licensed for MASH here ¹. Eligibility is based on the relevant criteria for those indications, and any liver-specific use is for a specialist to judge ¹².

Should I rely on Wegovy to treat my fatty liver?

No, not as a direct liver treatment, since it is not UK-licensed for MASH ¹. Weight management may be relevant to fatty liver through the weight link, but it does not replace the assessment and care your liver team provides, and any liver-specific role is for specialist judgement ¹².

Your next step

In the UK SmPC, Wegovy is licensed for weight management and cardiovascular risk reduction, not as a treatment for MASH or fatty liver disease, so this guide does not claim it as a UK liver-disease treatment. Weight management is generally relevant to fatty liver because the two are linked, but that is different from a licensed MASH indication, and the ESSENCE trial is beyond the UK licence and this guide's sources.

If you have fatty liver or MASH and obesity, weight management may be relevant through the weight connection, but it does not replace the assessment and care your liver team provides. Keep both teams informed, do not rely on a weight-loss medicine to treat your liver directly, and ask a clinician to put any trial findings like ESSENCE in context for you. If a UK liver indication is licensed in future, that is something updated guidance and your clinician would reflect, but the current UK position is what this guide is bound to, and overstating it would be misleading for a serious condition like liver disease that needs proper specialist care rather than assumptions. The honest summary is that addressing weight may help the factors behind fatty liver, while the liver condition itself stays under your specialist team, so the two are connected without a weight-loss medicine being a licensed UK treatment for the liver disease in its own right.

Disclaimer

This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.

If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.

If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.

References

1. Wegovy SmPC 4.1 (licensed indications: weight management and cardiovascular risk reduction; NO MASH/liver indication)
2. Semaglutide (used for obesity/weight management; general framing; fatty liver linked to weight; specialist management)